Pancreatic Cancer Research Team
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
- Conditions
- Pancreatic Ductal AdenocarcinomaPancreatic CancerPancreatic Neoplasms
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Pancreatic Cancer Research Team
- Target Recruit Count
- 35
- Registration Number
- NCT03634332
- Locations
- 🇺🇸
Banner Health - MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
- Conditions
- Resectable Pancreatic Cancer
- Interventions
- Drug: NGC-Triple regimen
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Pancreatic Cancer Research Team
- Registration Number
- NCT03392571
Project Survival-Prospective Biomarker Discovery
- Conditions
- Pancreatic CancerPancreatitisPancreatic AdenocarcinomaMetastatic Pancreatic CancerPancreatic Neoplasms
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pancreatic Cancer Research Team
- Target Recruit Count
- 436
- Registration Number
- NCT02781012
- Locations
- 🇺🇸
Banner Health - MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Pancreatic Cancer Research Team
- Target Recruit Count
- 25
- Registration Number
- NCT01893801
- Locations
- 🇺🇸
Scottsdale Health Care, Scottsdale, Arizona, United States
🇺🇸Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
🇺🇸Vita Medical Associates, PC, Bethlehem, Pennsylvania, United States
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- Genetic: Immunohistochemistry (IHC) AnalysisDrug: mFOLFIRI
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Pancreatic Cancer Research Team
- Target Recruit Count
- 60
- Registration Number
- NCT01488552
- Locations
- 🇺🇸
TGen Clinical Research Services (TCRS), Scottsdale, Arizona, United States
🇺🇸Disney Family Cancer Center, Burbank, California, United States
🇺🇸Virginia Piper Cancer Institute (VPCI), Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- Next